Trials / Completed
CompletedNCT00924443
A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable
A Phase II Trial of Clofarabine in Older Patients With Acute Myeloid Leukemia for Whom Intensive Chemotherapy is Not Considered Suitable
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine if treatment of older patients indicated with untreated Acute Myeloid Leukemia (AML) who are not considered to be suitable for intensive chemotherapy, can effectively be treated with Clofarabine.
Detailed description
Note: This clinical trial was conducted by Bioenvision Ltd. Bioenvision Ltd. was acquired by Genzyme Corporation Oct 2007.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | clofarabine |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2006-06-01
- Completion
- 2008-03-01
- First posted
- 2009-06-19
- Last updated
- 2015-04-01
- Results posted
- 2015-04-01
Locations
15 sites across 3 countries: Ireland, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT00924443. Inclusion in this directory is not an endorsement.